business case

Just a reminder to all of those that have lost faith, and the frustration waiting for sales...find below an extract from Stirlings web page on the business case..
------------------------------------------------------

The Intellectual Property and business case for Stirling 's products and pipeline future products is unique and is unmatched in today's market place.

The strengths of Stirling s investment and business case include:

Expanding Markets

The current global market for:

Botanical and plant-derived drugs is expected to increase from $19.5 billion in 2008 to $32.9 billion in 2013, a compound annual growth rate (CAGR) of 11.0%.

Human obesity products is valued well in excess of US$30 billion with over 65% of the western world population considered to be overweight or obese.

Medicated feed additives including growth agents, is estimated to be over US$4 billion globally.

Beta glucans continues to grow significantly with produce consumers wanting "chemical free" options. This nutritional feed additive market is estimated at over US$1 billion.



Defined Customer Need

All of the Stirling products and pipeline product candidates are positioned to address and provide solutions to existing demand and unmet needs. For example, the Stirling ST-810 beta agonist animal growth promoter is positioned to replace the use of antibiotics in the meat production industry; the botanical, Immunoxel is proving effective in the cure of all strains of TB, including Extremely Drug Resistant (XDR) TB and HIV co-infection which no other pharmaceutical drug has been able to achieve in the past 40 years; the human obesity application potential for ST-810 is positioned to meet a massive global demand for treatment of obesity and Stirlings ProVale is positioned as the worlds most pure and effective beta glucan.



Few Direct Competitors

Stirling is not aware of any other product that can match the demonstrated performance of Immunoxel in the treatment of TB and AIDS.

Stirling owns the Intellectual Property and patent rights to the worlds only single enantiomer beta agonist, R-Salbutamol, for use in human and animal obesity and for use as an animal growth promoter. R-Salbutamol is the worlds only growth promotion or obesity treatment beta agonist that has had a history over 30 years of safe human clinical use (for respiratory disease).

The ProVale beta glucans purity and effectiveness has demonstrated in comparison trials that it is the best in the market (greater than 80%) which leads to significantly improved animal and fish production and survival results.



Superior Safety and Efficacy Profiles

The purity of R-Salbutamol can maximise safety and efficacy over other racemic versions of beta agonists and thereby demonstrate economic potential and achieve industry support.



R-Salbutamol is the only beta agonist for growth promotion that has previous clinical use in humans to support its safety and efficacy. This safe human use for over 30 years in the treatment of respiratory disorders is expected to substantially support the re-purposing of the Stirling beta agonist for use in the treatment of human obesity.



Studies conducted with R-Salbutamol as a growth agent added to the feed for pigs, chicken, sheep and cattle, have already demonstrated superior efficacy for R-Salbutamol compared to current competition. This is particularly the case in feed efficiency and conversion, and in the repartitioning of metabolic energy providing carcasses with "more lean meat and less fat".



The Stirling botanical products have been available through Ukraine pharmacies for over 15 years and have been demonstrated to be completely safe with no evidence of any side effects.



Exclusivity

All of Stirling s products are covered by patents that afford excellent intellectual property protection. The earliest patents to expire provide coverage until 2018 and Stirling is in continued process of expansion and enhancement of Intellectual Property which is expected to lead to further patentable improvements that will substantively increase the life of all its patents respectively.

----------------------------------------------------

GOOD LUCK TO ALL HOLDERS